MaxCyte Stock

MaxCyte EBIT Margin

The EBIT Margin (Operating Margin) of MaxCyte (MXCT) as of Sep 5, 2026 is -132.54 %. In the previous year, EBIT Margin (Operating Margin) was -116.98 % — a change of 13.30% (lower).

EBIT Margin

-132.54 %

YoY

13.30%

Last updated:

EBIT Margin (Operating Margin) of MaxCyte is 2026 -132.54 % . EBIT Margin (Operating Margin) of MaxCyte was 2025 -116.98 % . It decreases by 13.30% lower compared to the previous year.

For MaxCyte, the operating (EBIT) margin of -132.5% is down versus -42.3% a few years ago.

The MaxCyte EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2017
-66.40 USD
Jan 1, 2018
-50.51 USD
Jan 1, 2019
-57.45 USD
Jan 1, 2020
-42.26 USD
Jan 1, 2021
-53.67 USD
Jan 1, 2022
-61.82 USD
Jan 1, 2023
-116.98 USD
Jan 1, 2024
-132.54 USD
The MaxCyte EBIT Margin history
YEAREBIT MarginYoY
-132.54 %+13.30%
-116.98 %+89.24%
-61.82 %+15.17%
-53.67 %+27.00%
-42.26 %-26.43%
-57.45 %+13.73%
-50.51 %-23.94%
-66.40 %+199.55%
-22.17 %+170.97%
-8.18 %-54.24%
-17.88 %+15,117.88%
-0.12 %-69.67%
-0.39 %
Access this data via the Eulerpool API

MaxCyte Stock analysis

What does MaxCyte do? MaxCyte Inc is a US biotechnology company specializing in the development of platform-based technologies for the next generation of gene and cell therapies. They offer integrated platform technology for drug manufacturing, research, and development. Their proprietary platform technology, Flow ElectroporationTM, allows for efficient transduction of a variety of cells, making it a valuable tool for the production of CAR-T cell therapies. They also offer services for lentiviral production and customized gene therapy production. MaxCyte has secured $50 million in funding for expansion and has formed important partnerships in the industry. They are a leading player in the development of innovative technologies for gene and cell therapy products. MaxCyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MaxCyte stock

EBIT Margin (Operating Margin) of MaxCyte is -132.54 % in 2026.

EBIT Margin (Operating Margin) of MaxCyte changed from -116.98 % to -132.54 %, representing a 13.30% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) MaxCyte since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s MaxCyte with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

Margins — MaxCyte

All Key Metrics — MaxCyte